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Abstract
Objective—MicroRNA expression in formalin fixed paraffin embedded tissue (FFPE) or plasma 
may add value for cancer management.
Methods—The GastroGenus miR Panel was developed to measure 55 cancer-specific human 
microRNAs, Epstein-Barr virus (EBV)-encoded microRNAs, and controls. This Q-rtPCR panel 
was applied to 100 FFPEs enriched for adenocarcinoma or adjacent non-malignant mucosa, and to 
plasma of 31 patients.
Results—In FFPE, microRNAs upregulated in malignant versus adjacent benign gastric mucosa 
were hsa-miR-21, -155, -196a, -196b, -185, and -let-7i. Hsa-miR-18a, 34a, 187, -200a, -423-3p, 
-484 and -744 were downregulated. Plasma of cancer versus non-cancer controls had upregulated 
hsa-miR-23a, -103 and -221 and downregulated hsa-miR-378, -346, -486-5p, -200b, -196a, -141 
and -484. EBV infected versus uninfected cancers expressed multiple EBV-encoded microRNAs, 
and concomitant dysregulation of four human microRNAs suggests that viral infection may alter 
cellular biochemical pathways.
Conclusion—Human microRNAs were dysregulated between malignant and benign gastric 
mucosa and between plasma of cancer patients and non-cancer controls. Strong association of 
EBV microRNA expression with known EBV status underscores the ability of microRNA 
Corresponding Author: Margaret L. Gulley, MD, Department of Pathology & Laboratory Medicine, Lineberger Comprehensive 
Cancer Center, University of North Carolina, 913 Brinkhous-Bullitt Building, Chapel Hill, NC 27599-7525, Telephone: (919) 
843-4595, margaret_gulley@med.unc.edu. 
Disclosure: The authors have no conflicts to disclose.
HHS Public Access
Author manuscript
Lab Invest. Author manuscript; available in PMC 2018 January 14.
Published in final edited form as:
Lab Invest. 2016 June ; 96(6): 661–671. doi:10.1038/labinvest.2016.33.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
technology to reflect disease biology. Expression of viral microRNAs in concert with unique 
human microRNAs provides novel insights into viral oncogenesis and reinforces the potential for 
microRNA profiles to aid in classifying gastric cancer subtypes. Pilot studies of plasma suggest 
the potential for a non-invasive addition to cancer diagnostics.
Keywords
Gastric adenocarcinoma; microRNA expression profile; Epstein-Barr virus; formalin fixed tissue; 
plasma; biomarker; Honduras
Gastric adenocarcinoma is the leading cause of infection-related cancer mortality and is 
projected to soon rise to eighth in all-cause mortality globally.1,2 Emerging data suggest that 
gastric adenocarcinoma is not one disease but rather has distinct molecular subtypes, 
including the Epstein-Barr virus (EBV)-infected subtype that comprises about 10% of all 
cases.3 In this subset of cancers, EBV DNA is localized within malignant cells. EBV was the 
first virus recognized to encode its own microRNAs. Like human microRNAs, viral 
microRNAs function post-transcriptionally to interfere with translation or promote mRNA 
degradation.
MicroRNAs are relatively stable in stored tissue or plasma specimens,4,5 and microRNA 
profiles are increasingly reported as ancillary markers of disease status. Formalin fixed, 
paraffin embedded tissue (FFPE) and blood plasma are the practical specimen types in 
which to examine a tumor’s biochemical profile because, unlike fresh or frozen tissue, these 
specimens are available for nearly every cancer patient. Blood plasma has recently been 
exploited in “liquid biopsy” assays of circulating microRNAs.6–9 Pertinent genomic 
technology such as Q-rtPCR can characterize microRNAs in tumor tissue and plasma, and 
clinical-grade quality assurance efforts are increasingly bringing RNA-based assays into the 
clinical arena.10
Prior discovery work found significantly altered microRNA expression profiles in gastric 
cancer compared to normal mucosa,11–18 and in blood of gastric cancer patients versus 
controls.7,8,11,19–24 In those studies, hsa-miR-21, hsa-miR-196a, and hsa-miR-196b were 
some of the most consistently altered microRNAs in gastric cancer despite marked 
variability in study designs and specimen types. Very few studies have taken into account the 
different molecular subtypes of gastric cancer, including EBV-positive cancers. In the 
current study, we designed a literature-based panel of the most dysregulated microRNAs in 
gastric cancer tissue or plasma, and then devised an analytic approach to measure these 
microRNAs in both fixed tissue and plasma, to examine suitability of this technology for 
distinguishing cancer, non-cancer, and EBV-infected cancer patients.
MATERIALS AND METHODS
DNA extraction
Formalin-fixed, paraffin-embedded gastric adenocarcinoma tissues from the clinical archives 
of three hospitals in disparate parts of the world were assembled. They included 21 from the 
University of North Carolina Hospitals in Chapel Hill (UNC), 55 from the Western Regional 
Hospital in Santa de Rosa de Copán, Honduras, and 2 from Wakayama Medical University 
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in Wakayama, Japan. Case selection was based on adequate FFPE tissue from either 
resection or biopsy specimens, with preference given to EBV-infected cancers in order to 
explore viral microRNA expression. Additionally, EDTA blood samples from 17 untreated 
UNC gastric adenocarcinoma patients (ages 51–88), and 14 blood samples from patients 
with no history of gastric cancer (ages 47–83, one of whom had a remote history of prostate 
cancer and the rest of whom had no cancer history) were used to prepare plasma for analysis 
of circulating cancer-related microRNAs. Plasma was not available from enough EBV-
positive gastric cancer patients to justify studies of circulating viral microRNAs. The study 
was approved by the Institutional Review Boards of the testing facilities.
Nine FFPE tissue sections, each 10 µM thick, were prepared from each block. A pathologist 
marked areas of tumor and benign mucosa (when available) on hematoxylin and eosin 
stained sections, and tumor and benign mucosa were separately macrodissected. When 
feasible, a separate tissue block was used as a source of benign mucosa. Total nucleic acid 
was extracted using the HighPure miR Isolation kit according to manufacturer instructions 
(Roche Applied Science, Mannheim, Germany). Following proteinase K treatment, the 
UniSp6 Exiqon control microRNA was spiked in. Eluate was treated with DNase and cDNA 
was prepared and stored at −20C until analysis.
Plasma was prepared by centrifugation (1500g for 10 minutes) of EDTA anticoagulated 
blood from gastric adenocarcinoma patients and non-carcinoma controls. A 200 µL aliquot 
of plasma was spiked with the Sp6 Exiqon control microRNA before nucleic acid extraction 
using the Exiqon miRCURY RNA Isolation Kit- Biofluids (Exiqon, Woburn, Massachusets). 
Eluate was treated with DNase, and cDNA was prepared and stored at −20C until analysis.
Q-rtPCR of microRNAs
A custom microRNA expression panel dubbed the GastroGenus miR Panel was devised to 
measure 51 unique target microRNAs chosen because they are reportedly gastric cancer-
specific, EBV-specific, or serve as endogenous markers of specimen quality. (See Table 1.) 
Spiked and no-template controls were also included to assess system performance.
Locked nucleic acid (LNA) technology is reported to yield precise and reproducible 
microRNA profiles.25 In this study, microRNA was measured by Q-rtPCR using 96-well 
plates preloaded with lyophilized miRCURY LNA Universal RT miR rtPCR primers 
(Exiqon, Woburn, MA) targeting 43 human microRNAs, one replicate, and 4 controls. A 
separate 10-well panel of Exiqon Q-rtPCRs was used to measure seven EBV microRNAs 
and three human microRNAs in the subset of cases with known EBV status. Expression was 
measured in real-time using SYBR Green detection on a Roche Lightcycler 480. Recovery 
of Sp6 microRNA that was spiked in prior to extraction served as a control for recovery and 
integrity of the stored nucleic acid and as a check for efficacy of downstream cDNA 
preparation and amplification. Lack of product in the no-spike controls (Sp2 and Cel-
miR-39-3p) on each plate, and consistent expression of Sp3 that is included in Exiqon 
reagents, demonstrated that the analytic test system performed as expected. Levels of Sp3 
also served as an interplate comparator, and expression of hsa-miR-191 served as a 
reproducibility control as it was tested twice on each panel.
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Prior to panel-based testing, cDNA prepared using the Exiqon Universal cDNA synthesis kit 
on 10 µL of eluate was vetted using individual Exiqon Q-rtPCRs targeting three human 
housekeeping microRNAs. Analytic capability to distinguish EBV-infected from uninfected 
cells, and lymphoid from epithelial cell lineage, was proven using FFPE cell pellets prepared 
from cultured cell lines (data not shown).
EBV Q-PCR and EBER in situ hybridization
EBV status was assigned in tumor tissue based on EBV DNA viral load exceeding a pre-
established threshold, or EBER localization to malignant cells. Q-PCR of the BamH1W 
segment of the EBV genome served to quantify EBV DNA viral load in plasma and in fixed 
tissue as previously described.3,26 EBV-encoded RNA (EBER) in situ hybridization (BOND 
assay, Leica Microsystems, Nussloch, Germany) results were used to localize EBV to 
malignant cells or to background lymphocytes, and oligo-dT control hybridization assured 
RNA was preserved in fixed tissues.27
Statistical analysis
Raw microRNA expression data were uploaded to the GenEx software platform (version 
6.0.1.612, MultiD Analyses AB). Raw data were calibrated using interplate calibrators. The 
NormFinder algorithm (in GenEx software) was applied to identify the most stably 
expressed subset of microRNAs in the data sets.28 These microRNAs with relatively stable 
expression across all samples allowed for data normalization, which helps control for 
differences in quantity and quality of amplifiable cDNA. In the human microRNA data set, 
32 microRNAs were identified as normalizers in FFPE, and 33 were identified in plasma. 
For the EBV microRNA data set, expression data were normalized to hsa-mir-423-3p, as it 
had the lowest variance of the 3 human microRNAs included in the 10-well test panel along 
with the 7 EBV microRNAs. The 7 EBV microRNAs had highly variable expression and 
could not be used as normalizers. Raw data were converted to relative expression by log2 
transformation. Significant differential expression between groups was determined using 
unpaired two-tailed t-tests. To maintain a type I error rate below 0.05, Dunn-Bonferroni 
correction was used to establish a significance threshold of p<0.00125 for the human miR 
panel, and p<0.00568 for the EBV-specific miRs. Unsupervised hierarchical clustering was 
performed using Ward’s algorithm with Pearson correlation as the distance metric for human 
microRNAs, and Euclidean distance for EBV microRNAs.
RESULTS
The GastroGenus miR Panel was applied to formalin-fixed tissue from 78 gastric 
adenocarcinoma specimens and 22 non-malignant gastric mucosa specimens. Three 
microRNAs (hsa-miR-1203, hsa-miR-371-1p, and hsa-miR-30e) were excluded from 
analysis due to low expression rates. After housekeeper microRNA normalization, 13 human 
microRNAs were significantly differentially expressed in tumor compared with non-
malignant gastric mucosa (p<0.00125). (See Figure 1A.) Of those, 6 were upregulated and 7 
were downregulated in tumor tissue. The upregulated microRNAs were hsa-miR-21, hsa-
miR-196a, hsa-miR-196b, hsa-miR-185, hsa-miR-155 and hsa-miR-let-7i. The 
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downregulated microRNAs were hsa-miR-187, hsa-miR-200a, hsa-miR-744, hsa-
miR-423-3p, hsa-miR-484, hsa-miR-34a and hsa-miR-18a.
A total of 32 microRNAs were identified as normalizers using the NormFinder algorithm on 
tissue specimens. (See Table 2.) Because 11 of these were also identified as being 
dysregulated in disease (10 of them altered in tumor compared to benign, and one additional 
altered in EBV-positive compared to EBV-negative tumors) a reanalysis of the data was 
performed excluding those 11 microRNAs as normalizers. Using the modified normalization 
strategy, the resulting lists of significantly dysregulated microRNAs were unchanged.
Unsupervised hierarchical clustering using the 13 significant microRNAs showed 90% 
accuracy in separation of cancer and non-malignant tissues (See Figure 2). Among the 10 
tissues that segregated incorrectly, 8 were non-malignant tissues exhibiting a cancer-like 
profile, and 2 were cancers exhibiting a benign-like profile. Four of the 8 misclassified 
benign samples were macrodissected from the same slide as their adenocarcinoma 
counterparts, suggesting occult tumor involvement of benign-appearing mucosa, or else 
“field effect” whereby adjacent benign-appearing tissue has biochemical features of 
malignancy. The remaining 4 misclassified benign samples were chronic gastritis lesions 
from gastric resection specimens located at a distance ranging from 1 to 7 cm from the 
corresponding adenocarcinoma. Both of the adenocarcinoma samples that clustered with the 
benign samples had low tumor content. One was a small focus of adenocarcinoma (2mm 
square) flanked by gastric mucosa. The other was a small gastric biopsy (4mm square) with 
approximately 50% adenocarcinoma cellularity. It is feasible that the surrounding mucosa in 
these 2 cases diluted adenocarcinoma-related microRNA signals.
Pilot studies of plasma microRNA profiles
The GastroGenus miR Panel was applied to plasma samples from 17 patients with untreated 
gastric cancer and to 14 plasmas from patients without a history of gastric cancer.
After housekeeper microRNA normalization, 11 human microRNAs were significantly 
differentially expressed in cancer versus non-cancer plasma (p<0.00125). Of the 11 
dysregulated microRNAs, 4 were upregulated and 7 were downregulated in cancer patient 
plasma. The four upregulated microRNAs were hsa-miR-23a, -103, -21, and -221, while the 
seven downregulated ones were -196a, -200b, -346, -378, -486-5p, 141 and -484.
A total of 33 microRNAs were identified as normalizers using the NormFinder algorithm on 
plasma specimens. Because 8 of these were dysregulated in cancer compared to non-cancer 
patients, these 8 microRNAs were excluded in a reanalysis of the plasma data. This 
renormalization resulted in loss of significance of miR-21; however, the remaining 10 
dysregulated microRNAs remained significant. (See Figure 1B.)
Unsupervised hierarchical clustering using the 8 most significant microRNAs showed 
excellent separation of tumor and non-tumor patients, with an accuracy of 100%. (See 
Figure 3.) Only two microRNAs, hsa-miR-196a and hsa-miR-484, were dysregulated in both 
cancer tissue and cancer patient plasma. While hsa-miR-484 was downregulated in both 
tissue and plasma, hsa-miR-196a was upregulated in cancer tissue and downregulated in 
Treece et al. Page 5
Lab Invest. Author manuscript; available in PMC 2018 January 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
plasma of cancer patients. This finding implies that tumor-derived microRNA is not 
necessarily informative when measured in plasma.
EBV-positive versus EBV-negative cancers
20 gastric adenocarcinomas were EBV-positive as defined by localization of EBV to 
malignant cells using EBER in situ hybridization or by high EBV DNA viral load using a 
validated Q-PCR of tumor tissue. Expression of 7 EBV microRNAs was examined in 17 
EBV-positive and 32 EBV-negative tumors for which sufficient tissue was available. All 7 
EBV microRNAs tested were upregulated in the EBV infected tumors (p<0.00568). The 
pattern of viral microRNA expression was consistent across all infected cancer tissues. (See 
Figure 4.) These findings are strong evidence that the analytic methods used to measure viral 
microRNAs in this study are sensitive and specific for identifying virus-infected cancers.
Four human microRNAs were significantly differentially expressed in EBV-positive 
compared with the EBV-negative tumors (p<.00125): hsa-miR-196b was downregulated 
while hsa-miR-155, hsa-miR-185 and hsa-miR-378 were upregulated in infected tumors. 
(See Figure 4.)
DISCUSSION
This study used modern molecular methods to show that selected human and viral 
microRNAs were differentially expressed in gastric cancer compared with non-cancer 
control tissues, and that EBV-infected cancers could be distinguished from uninfected 
cancers by virtue of viral miR expression. Circulating cell-free microRNA exhibited 
somewhat different patterns of microRNA expression than was found in primary tissues, yet 
the plasma profiles were found to distinguish cancer from non-cancer patient groups.
Benign and malignant tissues tended to cluster separately, with some exceptions that might 
be explained by field effect,29 by exosome or by other means of transfer of microRNA 
across cells in the microenvironment,30,31 by imperfect macrodissection, or by features such 
as inflammation that are common to both malignant and benign tissues.
Among the 6 microRNAs upregulated in our gastric cancer cohort compared to adjacent 
non-malignant gastric mucosa was hsa-miR-21, which was previously reported as 
overexpressed in gastric cancer tissues and in plasma of affected patients.18,32–39 The 
Cancer Genome Atlas Network showed that, compared to expression in non-malignant 
gastric mucosa, hsa-miR-21 was upregulated in all gastric cancer classes except for the 
“microsatellite instability” class.40,41 Utility in screening for recurrence is under 
investigation. Interestingly, hsa-miR-21 is induced by Helicobacter pylori co-culture with 
gastric epithelial cells.18
Hsa-miR-196a and -196b are strongly upregulated in gastric cancer tissues.11,42–45 In fact, 
The Cancer Genome Atlas Network showed that, compared with normal gastric mucosa, 
hsa-miR-196a and -196b were the top two most upregulated microRNAs in all molecular 
classes of gastric cancer except for the “EBV-positive” class.40,41
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The remaining three of our study’s upregulated microRNAs (hsa-miR-155, hsa-miR-185, 
and hsa-miR-let7i) have discordant reports in the literature suggesting either 
downregulation, utility as normalizers, or upregulation in gastric cancer cell lines and 
tissues.28,40,46–50 The Cancer Genome Atlas Network showed that, compared to normal 
mucosa, hsa-miR-155 and -185 are upregulated in the EBV-positive molecular class of 
cancer, while hsa-miR-185 is upregulated in the “chromosome instability” class of cancer 
that comprises 50% of all cases.40 Hsa-miR-155 reportedly acts to downregulate toll-like 
receptors after either bacterial or viral infection,51 raising the question of whether this miR 
contributes to Helicobacter pylori or EBV pathogenicity in gastric tissue. Of note, both of 
these pathogens as well as hsa-miR-155 upregulation are implicated in B lymphocyte 
proliferation and lymphomagenesis.52
Among the 7 microRNAs downregulated in our gastric cancer cohort compared to adjacent 
non-malignant gastric mucosa were hsa-miR-200a and hsa-miR-34a, which were previously 
shown to be downregulated in gastric cancer cell lines and tissues.53–56 However, hsa-
miR-18a has been reported to be upregulated in gastric cancer, and hsa-miR-187, hsa-
miR-484, and hsa-miR-744 are reportedly upregulated in sera of gastric cancer 
patients.20,21,23,57–60 Hsa-miR-423-3p was previously described as a normalizer.6
Eleven microRNAs were significantly dysregulated in our cohort of plasma samples. Hsa-
miR-221 and hsa-miR-23a were significantly upregulated while hsa-miR-200b and hsa-
miR-141 were downregulated, consistent with reported literature.7,20,61–71 The miR-200 
family, which includes miR-141 and mir-200b, are tumor suppressors implicated in 
epithelial to mesenchymal transition. They are known to be downregulated in association 
with EBV infection of epithelial cells.72 Hsa-miR-378 reportedly acts as a tumor suppressor 
and was downregulated in gastric cancer cell lines and in our cohort of plasmas, but a 
separate study reported upregulation in gastric cancer patient plasma.21,73,74 Association of 
hsa-miR-103 with gastric cancer is inconsistent in the literature, and it was also reported as a 
normalizer.75,76 Hsa-miR-486-5p was reportedly upregulated in the sera of gastric cancer 
patients, whereas it was downregulated in our cohort of plasmas.19,23 Hsa-miR-346 has not 
been described in gastric cancer, although it is reportedly induced by EBV infection in B 
lymphocytes.77
Only hsa-miR-21, -196a, and -484 were significantly dysregulated in both gastric cancer 
tissue and in patient plasma. Hsa-miR-21 was increased, while hsa-miR-484 was diminished 
in both cancer tissue and plasma; however, hsa-miR-21 was considered borderline 
significant for dysregulation in plasma since it was impacted by choice of normalization 
strategy.
Surprisingly, the directionality of hsa-miR-196a was different in the two specimen types, 
with upregulation in cancer tissue but relatively low levels found in cancer patient plasma. A 
recent review78 of published studies demonstrated that, out of 154 expression profiles 
reported, only 7% showed statistically significant dysregulation in the same direction in both 
tissue and the circulation, while an additional 7% showed dysregulation in the opposite 
direction between these specimen types. The data challenge the notion that microRNA 
signatures in the circulation correspond to those of tumor tissue. Though the reasons for 
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such discrepancies are not fully understood, possible explanations include selective release 
of microRNAs from cells, inflammatory and other systemic responses to disease, or 
differences in stability of a microRNA that could relate to whether it is protected inside 
exosomes. These discrepancies have implications for the development of clinical assays, 
reinforcing that each specimen type must be separately validated.
Hsa-miR-21 is one of the most thoroughly studied microRNAs and has been reported in 
numerous cancer types. Both hsa-miR-21 and -155 are associated with inflammation.79 In 
our study, these two microRNAs were upregulated in cancer tissue only, not in plasma. Prior 
studies have confirmed expression of hsa-miR-21 in gastric cancer, while hsa-miR-155 
upregulation is associated with EBV-positive gastric cancers.18,40 None of the microRNAs 
we report as dysregulated in plasma has been consistently associated with inflammation.
79,80
EBV-infected gastric cancer tissue had exceedingly high levels of most EBV microRNAs. 
Of the seven viral microRNAs tested, those most highly overexpressed in infected cancers 
were EBV-miR-BART 7-3p, 1-5p, and 17-3p. Even EBV-miR-BHRF1-2-5p, not previously 
reported to be expressed in gastric cancer, was revealed to be differentially overexpressed in 
infected compared to uninfected cancer tissues, albeit at lower levels than the six 
microRNAs encoded from the BART region of the viral genome. The findings may indicate 
low-level viral replication in cancer tissues having viral EBNA1 expression from the Cp or 
Wp promoters.81 Marquitz et al reported expression of the same group of viral microRNAs 
in infected epithelial cell lines and xenografts, although BART 10-5p expression appears to 
be low or absent in laboratory models.72 Our demonstration of similar viral expression 
profiles across all 17 infected cancer tissues suggest the potential to use viral microRNA 
expression patterns as a means of identifying infected cancers.
In addition to EBV-encoded microRNAs, we identified 4 human microRNAs that were 
differentially expressed in the EBV-infected subset of gastric cancer tissues. Hsa-miR-155, 
-185 and -378 were upregulated in infected cancer, while hsa-miR-196b was downregulated 
in infected cancer. All four of these microRNAs have been described as being dysregulated 
in gastric cancer tissue or plasma, and hsa-miR-155 is known to be induced by 
EBV.21,44,45,47,48,73,74,82,83 Hsa-miR-200a was previously reported to be downregulated by 
EBV,84 and we observed this same trend, but this association did not reach significance 
following Bonferroni correction. Nevertheless, the unique pattern of human microRNA 
dysregulation seen in association with EBV infection suggests that the virus is not an 
innocent bystander when it is present within malignant cells.
Identification of infected cancers is important because of their favorable prognosis85 and 
because of the potential for enrollment in clinical trials exploring virus-targeted therapy 
(NCT00982449 or NCT02080416 at clinicaltrials.gov). Anti-neoplastic strategies include 1) 
infused EBV-specific cytotoxic T cells,86–89, 2) reversing EBV-related hypermethylation,90 
3) inciting the body’s innate and adaptive antiviral immune responses,91–99 and 4) 
capitalizing on expression of a viral enzyme to convert a drug (such as gancyclovir) to its 
cytotoxic form.100–107 Laboratory support for such clinical trials requires assays to predict 
which candidates are likely to respond, and serial assays that reflect tumor burden or that 
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assess biochemical effects on pertinent pathways. MicroRNA profiling shows promise for 
these purposes.
Cell-free microRNAs in plasma might serve as non-invasive indicators of disease status that 
could form the basis for cancer screening programs. Proof of principle is already established 
for EBV DNA measurement as a harbinger of progression to EBV-driven post-transplant 
lymphoproliferations. Emerging data suggest that viral microRNA profiling might add value 
beyond EBV DNA viral load based on the spectrum of microRNA expression in benign 
versus malignant infections.108 Furthermore, levels of viral microRNA appear to be much 
higher than viral DNA, potentially yielding improved sensitivity for low-level disease.
Review of the literature reveals marked variability in specimen type, study design, methods, 
and identification of candidate microRNAs. Accurate interpretation of the body of 
experimental microRNA data is further complicated by the fact that gastric adenocarcinoma 
is not one disease but rather is a divided into histologic subtypes, with varying degree of 
cytologic and neuroendocrine differentiation and varying levels of inflammatory infiltrates. 
Though studies of single microRNAs have shown some promise for diagnosis and 
prognosis, the use of a panel of microRNAs will likely yield increased sensitivity and 
specificity. Our findings encourage further work to validate such a panel on patients with 
cancer and relevant comparator populations.
This study demonstrates the potential for microRNA profiling to distinguish cancer from 
normal tissue, and to subclassify cancer based on virus-encoded and associated human 
microRNA expression patterns. This study reinforces applicability of microRNA profiling to 
practical clinical specimens including small biopsies and plasma, thus highlighting its appeal 
for practice of laboratory medicine. Q-rtPCR profiling is facilitated by commercial 
availability of pre-loaded 96-well plates containing lyophilized primers that can be 
customized for the analytes of interest. Large panels of tests, including multiple controls, 
promote confidence in the findings. The strong association between EBV microRNA 
expression and known EBV status by clinical-grade assays verifies that the test system 
performs well. The protocols described herein reflect the type of technology that could 
support clinical trials and, once validated as adding value in patient management, could be 
implemented in routine patient care.
We verified a subset of the previously reported human microRNA associations. Varying 
analytic methods undoubtedly contribute to divergent data in the literature, which 
underscores the need to continue to gather evidence of analytic and clinical performance of 
specified microRNA test protocols in large groups of subjects.109 In paraffin embedded 
tissue, we envision that ancillary microRNA profiling could help resolve whether invasive 
cancer is present. This technology may add value in small biopsies or when the tissue is 
poorly oriented in a paraffin block. In plasma, future work should explore microRNA 
profiling as a means of monitoring tumor burden during therapy, or as a harbinger for initial 
diagnosis or for relapse.
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Figure 1. 
Differential expression of microRNAs in cancer tissue compared with benign mucosa, and in 
cancer patient plasma compared with control plasma. (A) In formalin fixed tissues, thirteen 
microRNAs were significantly dysregulated (adjusted p<0.00125) in gastric cancer tissue 
compared with non-cancer. (B) In plasma, ten microRNAs were significantly dysregulated 
(adjusted p<0.00125) in gastric cancer patients compared with the control cohort lacking 
gastric cancer. Box plots represent the median (dotted line) and middle quartiles; whiskers 
are 1.5*interquartile range.
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Figure 2. 
MicroRNA expression patterns differ between malignant tissue and benign mucosa. 
Unsupervised hierarchical clustering of 78 gastric cancers (red) and 22 benign gastric 
mucosal (blue) reveal that expression profiles of 13 significantly dysregulated microRNAs 
discriminate benign from malignant tissue with 90% accuracy.
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Figure 3. 
Plasma microRNA expression patterns differ in gastric cancer patients and in non-cancer 
controls. A heat map created by unsupervised hierarchical clustering of plasma levels for the 
eight most significantly differentially expressed microRNAs reveals perfect discrimination 
of disease categories. Each column is a different patient with either gastric cancer or no 
history of gastric cancer. Red color intensity corresponds to increased expression and green 
color intensity corresponds to decreased expression.
Treece et al. Page 18
Lab Invest. Author manuscript; available in PMC 2018 January 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Differential expression of viral and associated human microRNAs suggests that Epstein-Barr 
virus (EBV) infected cancers are biologically distinct from uninfected cancers. (A) EBV-
positive compared with EBV-negative cancer tissue has significant dysregulation of four 
human microRNAs (p<0.00125). All seven EBV microRNAs that were examined were 
expressed at higher levels in EBV-positive compared to EBV-negative cancers (adjusted 
p<0.00568). Note the wide dynamic range of expression for the viral microRNAs, signifying 
high levels of expression of several viral microRNAs in the circulation of infected cancer 
patients. Box plots represent the median (dotted line) and middle quartiles; whiskers are 
1.5*interquartile range. (B) Patterns of viral microRNA expression were similar across the 
17 infected gastric cancers.
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Table 1
Target microRNAs in the GastroGenus miR Panel
Target microRNA References Target microRNA References
hsa-let-7e 25 hsa-miR-196a 11
hsa-let-7i 26 hsa-miR-196b 27
hsa-miR-16 19, 28 hsa-miR-200a 29
hsa-miR-17 23, 24 hsa-miR-200b 29, 30
hsa-miR-18a 31 hsa-miR-221 7, 20
hsa-miR-19a 17 hsa-miR-222 20
hsa-miR-20a 7, 23, 32 hsa-miR-370 12
hsa-miR-21 24, 33 hsa-miR-371-5p 21
hsa-miR-23a 6, 26 hsa-miR-376c 20
hsa-miR-23b 26 hsa-miR-378 21
hsa-miR-25 19, 23 hsa-miR-423-3p 6
hsa-miR-27a 32 hsa-miR-425 26
hsa-miR-27b 20 hsa-miR-451 19, 34
hsa-miR-30e 26 hsa-miR-484 23
hsa-miR-346 35 hsa-miR-486-5p 19, 23
hsa-miR-34a 36 hsa-miR-744 20
hsa-miR-93 26, 28 hsa-miR-1203 23
hsa-miR-103 37 ebv-miR-BART 1-5p 38
hsa-miR-106a 23, 24 ebv-miR-BART 10-5p 38
hsa-miR-106b 7, 24 ebv-miR-BART 12 38
hsa-miR-141 36, 39 ebv-miR-BART 17-3p 38
hsa-miR-146a 40 ebv-miR-BART 7-3p 38
hsa-miR-155 41 ebv-miR-BART 7-5p 38
hsa-miR-185 26 ebv-miR-BHRF 1-2-5p 38
hsa-miR-187 21 UniSp2 negative control 6
hsa-miR-191 20 UniSp3 reagent positive control 6
hsa-miR-191 (replicate) 20 UniSp6 spiked control 6
Cel-miR-39-3p negative control
Lab Invest. Author manuscript; available in PMC 2018 January 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Treece et al. Page 21
Table 2
MIcroRNAs Identified as normalizers, ranked from major to minor in terms of stability across all tissue or 
plasma specimens
Normalizers
in tissue
Average
Expression
Normalizers
in plasma
Average
Expression
hsa-miR-191 Medium hsa-miR-106a High
hsa-miR-191 (replicate) Medium hsa-miR-25 Medium
hsa-let-7i1 Medium hsa-miR-191 Medium
hsa-miR-423-3p1 Medium hsa-miR-106b Low
hsa-miR-25 Medium hsa-miR-1411 Low
hsa-miR-93 Medium hsa-miR-370 Low
hsa-miR-27a Medium hsa-miR-20a High
hsa-let-7e Medium hsa-miR-191 (replicate) Medium
hsa-miR-222 High hsa-miR-222 Medium
hsa-miR-425 Medium hsa-miR-23b Medium
hsa-miR-376c Low hsa-miR-4841 High
hsa-miR-4841 Medium hsa-miR-146a Medium
hsa-miR-146a Medium hsa-let-7i Medium
hsa-miR-221 Medium hsa-miR-155 Medium
hsa-miR-27b Medium hsa-miR-93 High
hsa-miR-7441 Low hsa-miR-196b Medium
hsa-miR-20a Medium hsa-miR-3781 Medium
hsa-miR-103 Medium hsa-miR-34a Low
hsa-miR-18a1 Medium hsa-miR-16 High
hsa-miR-370 Low hsa-miR-23a1 High
hsa-miR-23a High hsa-miR-17 Medium
hsa-miR-16 Medium hsa-miR-423-3p Medium
hsa-miR-23b High hsa-miR-425 Medium
hsa-miR-3781 Medium hsa-miR-200a Low
hsa-miR-106b Low hsa-miR-486-5p1 High
hsa-miR-211 High hsa-miR-211 Medium
hsa-miR-1851 Medium hsa-let-7e Medium
hsa-miR-106a Medium hsa-miR-27a Medium
hsa-miR-17 Low hsa-miR-744 Medium
hsa-miR-34a1 Medium hsa-miR-376c Medium
hsa-miR-1551 Medium hsa-miR-1031 Medium
hsa-miR-196b1 Medium hsa-miR-200b1 Low
hsa-miR-27b Medium
1
microRNAs identified as nomalizers and also associated with disease status in the corresponding sample type
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